Idera Pharmaceuticals has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Idera Pharmaceuticals, 2017, NOV 6, 2017, View Source [SID1234521597]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 6, 2017 Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient’s immune system against cancer, reported that it will deliver pre-clinical data on its Combination Pan-antigen Cytotoxic Therapy (ComPACT) platform on November 11, 2017, at the 32nd annual Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) (Press release, Heat Biologics, NOV 6, 2017, View Source [SID1234521582]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, Gp96-IG/costimulatory Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination, will be presented by Louis E. Gonzalez, Ph.D., director of research and principal scientist for Heat. He is available for discussion from 12:30 p.m. – 2 p.m. and 6:30 p.m. – 8 p.m. on Saturday, Nov. 11, 2017.

ComPACT is Heat’s next generation, T-cell Activation Platform (TCAP). It combines T-cell activation and co-stimulation in a single therapy by both delivering the gp96 heat shock protein and a T-cell co-stimulatory fusion protein (OX40L) in a single compound.

On November 6, 2017 Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, reported that the company is moving its conference call that was scheduled for 5:00 p.m. ET today to 8:00 a.m. ET tomorrow morning (Press release, Keryx Biopharmaceuticals, NOV 6, 2017, View Source;p=RssLanding&cat=news&id=2314738 [SID1234521608]). The company’s Prescription Drug User Fee Act (PDUFA) target action date for its supplemental new drug application for Auryxia is today, November 6, 2017. As of the time of this press release, the company has not received a response from the FDA. As such, Keryx has decided to move its third quarter financial results call to tomorrow.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 2193619. The call will be webcast live and accessible through the Investors section of the company’s website at www.keryx.com for a period of 15 days after the call.

Five Prime Therapeutics has filed a 10-Q – Quarterly report [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 10-Q, Five Prime Therapeutics, 2017, NOV 6, 2017, View Source [SID1234521598]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 6, 2017 OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, reported 14, 2017, after the close of the U.S. financial markets (Press release, BioTime, NOV 6, 2017, View Source [SID1234521579]). The Company will host a conference call on Tuesday, November 14, 2017, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results along with recent corporate developments.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dial-in number in the U.S./Canada is 888-542-1102, for international participants the number is 719-325-2356. For all callers, refer to Conference ID 1817036. To access the live webcast, go to the investor relations section on the company’s website, View Source

A replay of the conference call will be available for seven business days beginning about two hours after the conclusion of the live call, by calling 888-203-1112 toll-free (from U.S./Canada); international callers dial 719-457-0820. Use the Conference ID 1817036. Additionally, the archived webcast will be available View Source